Methods of administering N- (5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-m orpholin4-yl-ethoxy)imidazo[2,1-b][1,3]benzothi azol-2-yl]phenyl}urea to treat proliferative disease

Details for Australian Patent Application No. 2008325141 (hide)

Owner Ambit Biosciences Corp.

Inventors James, Joyce K.; Savall, Traci L.; Eichelberger, Shawn R.

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2008325141

PCT Pub. Number WO2009/061446

Priority 61/098,676 19.09.08 US; 61/002,583 08.11.07 US; 61/112,060 06.11.08 US; 61/005,803 07.12.07 US

Filing date 7 November 2008

Wipo publication date 14 May 2009

International Classifications

A61K 31/5377 (2006.01)

A61P 35/00 (2006.01) Antineoplastic agents

A61P 35/02 (2006.01) Antineoplastic agents

Event Publications

18 March 2010 PCT application entered the National Phase

  PCT publication WO2009/061446 Priority application(s): WO2009/061446

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008325142-Use of umbilical cord blood in the treatment of premature birth complications

2008325140-Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction